Postech Academy-industry Foundation

Posco

Postech Foundation

Seoul National University

Yonsei University

Ulsan National Institute of Science and Technology

Unist, Inc.

Sung Ho Ryu

Pann-Ghill Suh

Jong Hun Im

Jung Hwan Lee

Jong In Kim

Sung Key Jang

Young Chan Chae

Youndong Kim

Hye Jung Lee

Eun Ju Oh

Mi-Jin Kwon

Soon Hag Kim

Hyungu Kang

Ki Seok Kim

Sun Hak Lee

Eun Jung Jang

Soyeon Park

Dohyeon Kim

Yong Song Gho

Jeong-Hoon Lee

Yoon Keun Kim

Narayanan Selvapalam

Yoe-Sik Bae

Jun Ho Chung

Kyung Lock Kim

Kyeng Min Park

Jong-Hoon Lim

Taehoon Lee

Jong-young Kwak

Richard D Ye

You Me Tae

Won Jun Kang

Hyun Tae Jung

Ji Ho Yoo

Don Wook Lee

Yu Jin Lee

Yonghoon Kwon

Jung-Im Kim

Eun Jin Jo

Ha Young Lee

Tae Hoon Lee

Kyong-Tai Kim

Mi-Sook Lee

Yun-Hee Kim

Hyun-Kyu Kang

Seungmin Han

Jiyoun Lee

Sehoon Park

Jung Hwan Yoon

Ara Koh

Su Min Yoon

Dong Kyun Kim

Yoon Sup Choi

Na-Oh Yunn

Eun-Mi Hur

Kai Zhou

Ii Shin Kim

Youn Dong Kim

A Ra Koh

Mi Nam Lee

Hee Yoon Jeong

Yong Ryoul Yang

Pann Ghill Suh

Hyun Soo Cho

Sang Uk Kim

Ki Moon Kim

Sang Hoon Ha

Banerjee Mainak

Seong Hui Jin

Nam Ki Lee

Wan-Uk Kim

Yoe Sik Bae

Byoung Dae Lee

SooMi Kim

Yong-Soo Park

Il Shin Kim

The present disclosure relates to a DNA aptamer which specifically binds to an insulin receptor, and a composition for treating diabetes and a composition for diagnosing diabetes which contain the same as an active ingredient, and the aptamer is characterized by being able to treat and diagnose diabetes more effectively than side effects caused by insulin such as increased incidence of cancer and atherosclerosis by having a different binding mechanism from existing insulin.

Aptamer against insulin receptor and pharmaceutical compostion containing the same

The present invention relates to a DNA aptamer specifically binding to a hepatocellular carcinoma-related Glypican-3 (GPC3) protein, treatment of cancers related to the Glypican-3 protein using the same, a composition for inhibiting a cancer and a composition for diagnosing a cancer comprising the same as an active ingredient.

Glypican-3 specific aptamer and use thereof

The present invention relates to a method for analyzing the pattern of live intercellular membrane protein binding. The method for analyzing the pattern according to the present invention can analyze accurately, sensitively, quickly, and readily the binding pattern of a target membrane protein and a candidate substance to be specifically bound therewith without tagging to a ligand, and thus measure directly and accurately the position and quantitative information of the binding of the membrane protein and the target substance. Such effects make it possible to apply the method for various uses such as dissociation constant, mutant study, complex formation, and signal transduction. Moreover, it is expected to use the method for searching out undiscovered membrane proteins and target substances.

Method of analyzing binding aspect of membrane protein in a living cell

This disclosure relates to DNA aptamer specifically binding to periostin, which is cancer-related protein, a composition for inhibiting cancer and/or cancer metastasis and/or a composition for diagnosis of cancer and/or cancer metastasis, comprising the same as an active ingredient, wherein the aptamer has different binding mechanism from the existing antibodies, and thus, may inhibit and diagnose cancer/cancer metastasis more effectively.

Aptamer for periostin and anti-cancer composition including same

The present invention relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which includes a TENC1 (tensin like C1 domain-containing phosphatase) expression or activity suppressor, and, more specifically, relates to a pharmaceutical composition for preventing or treating diabetes or a complication of diabetes, which either suppresses the degradation of IRS-1 (insulin receptor substrate-1) or suppresses the phosphorylation of IRS-1 due to the PTPase activity of TENC1. The pharmaceutical composition according to the present invention, which is for preventing or treating diabetes or a complication of diabetes and comprises the TENC1 expression or activity suppressor as an active ingredient, can be expected to be widely usable in preventing and treating diabetes or a complication of diabetes since the pharmaceutical composition can effectively prevent the muscular dystrophy and reduction in sugar adsorption that occur due to reduction in IRS-1 by suppressing degradation of IRS-1 caused by TENC1.

Pharmaceutical composition for preventing or treating diabetes containing TENC1 expression or activity suppressor

The present invention relates to a method for preparing a target-specific non-antibody protein, and more particularly, to a method for preparing a target-specific non-antibody protein comprising the steps of: selecting non-antibody proteins having a structural complementarity with the target site of a target protein in a non-antibody protein library; calculating a binding energy of the selected non-antibody protein and the target protein; selecting a non-antibody protein having a favorable binding energy among the selected non-antibody proteins; selecting amino acid residues having a high binding energy among the interfacial amino acid residues of the selected non-antibody protein and the target protein; and substituting the selected amino acid residues with the amino acid residues having a low binding energy. In addition, the present invention relates to a target-specific non-antibody specifically binding with EGFR (Epidermal Growth Factor Receptor) domain 2, which is prepared by the method, and a cancer therapeutic composition comprising the same.

Target-specific non-antibody protein and method for preparing the same

Provided is a method of separating cellular components, the method including: a) contacting a guest compound-bound reactive compound with cells; b) lysing the cells; c) adding a host compound-bound solid phase to a solution including the lysates of the cells to prepare a mixture; d) separating binding pairs of the guest compound bound to cellular components and the host compound bound to the solid phase from the mixture, and purifying the binding pairs; and e) separating the cellular components from the binding pairs, wherein the guest compound-bound reactive compound is obtained through a covalent bond between a reactive compound and a guest compound represented by Formula 2 below guest, the host compound-bound solid phase is obtained through a covalent bond between a solid phase and a host compound represented by Formula 1 below, and the reactive compound includes at least one selected from the group consisting of a biomolecule, N-hydroxysuccimide, an antigen, an antibody, an aptamer, folic acid, transferrin, and any mixtures thereof.

Method of separating and purifying cellular components using non-covalent bond between cucurbituril derivative and guest compound and apparatus using the same

Improved G-rich oligonucleotide (GRO) aptamers specific to nucleolin, a method of preparing the aptamers, and a use of the aptamers for diagnosing and/or treating a nucleolin-associated disease, are provided.

Method of diagnosing cancer using a nucleolin specific aptamer

Method of treating hyperproliferation of cells using a nucleolin specific aptamer

This disclosure relates to an angiogenesis-related pharmaceutical composition using connective tissue growth factor, more particularly to a pharmaceutical composition for promoting angiogenesis containing the connective tissue growth factor or a pharmaceutical composition for inhibiting angiogenesis containing at least one selected from the group consisting of polypeptide, antibody and a compound binding to connective tissue growth factor. The fragment of connective tissue growth factor protein, which was found out in the present invention, is a binding region to FPRL1, effectively induces FPRL1-specific ERK phosphorylation, activates FPRL1 to increase intracellular Caconcentration, and finally, effectively induces angiogenesis, and thus, the fragment of connective tissue growth factor may be useful for a pharmaceutical composition for promoting angiogenesis, while polypeptide, antibody or a compound binding to the fragment of connective tissue growth factor protein may be useful for a pharmaceutical composition for inhibiting angiogenesis.

Pharmaceutical composition using connective-tissue growth factor

The present application relates to a pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, comprising a peptide which acts on formyl peptide receptors (FPRs) or receptors analogous thereto, in an amount which is effective in suppressing respiratory inflammation. The present application also relates to a method for treating or preventing inflammatory respiratory diseases by using the preparation, and to a kit containing the preparation. As compared with systemic administration of the peptide by injection, direct administration of the peptide to respiratory organs remarkedly improves the effect in suppressing respiratory inflammation.

Pharmaceutical preparation to be administered into respiratory organs for treating or preventing inflammatory respiratory diseases, and method for treating or preventing such diseases

The present invention relates to a method of protecting cells against damage caused at least in part by apoptosis, comprising administering to subjects a therapeutic dose of leumorphin having cytoprotective activity, and a pharmaceutical composition comprising an effective amount of leumorphin having a cytoprotective activity.

Method of protecting cells against damage and pharmaceutical composition comprising leumorphin

The present application discloses W-rich peptide that is useful for inhibiting FPR class receptor activity.

Peptides that antagonize FPR class receptor mediated signaling

Growing community of inventors

Pohang-si, South Korea

Sung Ho Ryu